Abstract
The number of gene mutations involved in the hereditary spastic paraplegias is rapidly growing due to the expansion of the frontiers of genomic research by next-generation DNA sequencing platforms. Nevertheless, a comprehensive genetic diagnosis method remains yet unavailable for these diseases. In the current research, an 8-year-old boy with short stature and developmental delay impairment, from a nonconsanguineous family, was referred to our genetic lab. Firstly, based on the physician recommendation, the patient was evaluated by tandem mass spectrometry (MS/MS) for the quantitative examination of amino acids, and then the patient was genetically investigated by karyotype analysis and whole-exome sequencing (WES) technique. Subsequently, targeted Sanger sequencing was applied to confirm the presence of the candidate variant in all the members of the family and screening the other patients for Troyer syndrome. Analysis of inherited metabolic disorders by tandem MS/MS showed the state of all the family members as normal and also karyotyping indicated no chromosomal aberration in the patient. Further investigation by WES technique indicated a homozygous missense variant in the SPG20 gene, c.1006C>T. Targeted sequencing result of the mutation confirmed homozygote state for the affected case and a heterozygote genotype for his parents. The mutation was classified as pathogenic. Detection of novel variants especially pathogenic variant in the SPG20 gene was associated with Troyer syndrome, which encodes a multifunctional protein termed Spartin, assist in improving genotype‒phenotype correlation of genetic variants and may facilitate initial diagnosis of Troyer syndrome.
This is a preview of subscription content, log in via an institution to check access.
Reference
Alazami A. M., Patel N., Shamseldin H. E., Anazi S., Al-Dosari M. S. Alzahrani F et al. 2015 Accelerating novel candidate gene discovery in neurogenetic disorders via whole-exome sequencing of prescreened multiplex consanguineous families. Cell Rep. 10, 148–161.
Bakowska J. C., Wang H., Xin B., Sumner C. J. and Blackstone C. 2008 Lack of spartin protein in Troyer syndrome: a loss-of-function disease mechanism? Arch. Neurol. 65, 520–524.
Bross P., Naundrup S., Hansen J., Nielsen M. N., Christensen J. H., Kruhøffer M. et al. 2008 The Hsp60-(p. V98I) mutation associated with hereditary spastic paraplegia SPG13 compromises chaperonin function both in vitro and in vivo. J. Biol. Chem. 283, 15694–15700.
Butler S., Helbig K. L., Alcara W., Seaver L. H., Hsieh D. T. et al. 2016 Three cases of Troyer syndrome in two families of Filipino descent. Am. J. Med. Genet. Part A 170, 1780–1785.
Dardour L., Roelens F., Race V., Souche E., Holvoet M. and Devriendt K. 2017 SPG20 mutation in three siblings with familial hereditary spastic paraplegia. Cold Spring Harb. Mol. Case Stud. 3, a001537.
Diquigiovanni C., Bergamini C., Diaz R., Liparulo I., Bianco F., Masin M. et al. 2018 In Troyer syndrome Spartin loss induces complex I impairments and alters pyruvate metabolism. bioRxiv: 488239.
Eastman S. W., Yassaee M. and Bieniasz P. D. 2009 A role for ubiquitin ligases and Spartin/SPG20 in lipid droplet turnover. J. Cell Biol. 184, 881–894.
Karlsson A. B., Washington J., Dimitrova V., Hooper C., Shekhtman A. and Bakowska J. C. 2014 The role of spartin and its novel ubiquitin binding region in DALIS occurrence. Mol. Biol. Cell 25, 1355–1365.
Lossos A., Stümpfig C., Stevanin G., Gaussen M., Zimmerman B.-E. and Mundwiller E. et al. 2015 Fe/S protein assembly gene IBA57 mutation causes hereditary spastic paraplegia. Neurology 84, 659–667.
Manzini M. C., Rajab A., Maynard T. M., Mochida G. H., Tan W. H., Nasir R. et al. 2010 Developmental and degenerative features in a complicated spastic paraplegia. Ann. Neurol. 67, 516–525.
Patel H., Cross H., Proukakis C., Hershberger R., Bork P. et al. 2002 SPG20 is mutated in Troyer syndrome, an hereditary spastic paraplegia. Nat. Genet. 31, 347.
Proukakis C., Cross H., Patel H., Patton M. A., Valentine A., Crosby A. H. et al. 2004 Troyer syndrome revisited. J. Neurol. 251, 1105–1110.
Renvoisé B., Parker R. L., Yang D., Bakowska J. C., Hurley J. H., Blackstone C. et al. 2010 SPG20 protein spartin is recruited to midbodies by ESCRT-III protein Ist1 and participates in cytokinesis. Mol. Biol. Cell 21, 3293–3303.
Renvoisé B., Stadler J., Singh R., Bakowska J. C. and Blackstone C. 2012 Spg20−/− mice reveal multimodal functions for Troyer syndrome protein spartin in lipid droplet maintenance, cytokinesis and BMP signaling. Hum. Mol. Genet. 21, 3604–3618.
Shanmughapriya S., Rajan S., Hoffman N. E., Higgins A. M., Tomar D., Nemani N. et al. 2015 SPG7 is an essential and conserved component of the mitochondrial permeability transition pore. Mol. Cell 60, 47–62.
Shimazaki H., Takiyama Y., Ishiura H., Sakai C., Matsushima Y., Hatakeyama H. et al. 2012 A homozygous mutation of C12orf65 causes spastic paraplegia with optic atrophy and neuropathy (SPG55). J. Med. Genet. 49, 777–784.
Spiegel R., Soiferman D., Shaag A., Shalev S., Elpeleg O. and Saada A. et al. 2016 Novel homozygous missense mutation in SPG20 gene results in Troyer syndrome associated with mitochondrial cytochrome c oxidase deficiency. JIMD Rep. 33, 55–60.
Tawamie H., Wohlleber E., Uebe S., Schmäl C., Nöthen M. M., Jamra R. A. et al. 2015 Recurrent null mutation in SPG20 leads to Troyer syndrome. Mol. Cell. Probes 29, 315–318.
Yang D., Rismanchi N., Renvoisé B., Lippincott-Schwartz J., Blackstone C., Hurley J. H. et al. 2008 Structural basis for midbody targeting of spastin by the ESCRT-III protein CHMP1B. Nat. Struct. Mol. Biol. 15, 1278.
Yang Y., Liu W., Fang Z., Shi J., Che F., He C. et al. 2016 A newly identified missense mutation in FARS2 causes autosomal-recessive spastic paraplegia. Hum. Mut. 37, 165–169.
Author information
Authors and Affiliations
Corresponding author
Additional information
Corresponding editor: S. Ganesh
Rights and permissions
About this article
Cite this article
Khoshaeen, A., Najafi, M., Mahdavi, M.R. et al. A novel missense mutation (c.1006C>T) of SPG20 gene associated with Troyer syndrome. J Genet 99, 55 (2020). https://doi.org/10.1007/s12041-020-01210-0
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12041-020-01210-0